Cargando…
Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers
INTRODUCTION: Immune checkpoint inhibitors (ICIs) are approved in multiple indications for cancer care. Most of the clinical trials have not questioned shorter than until disease progression approaches. In this study, we present results from a cohort of multiple advanced cancers treated with restric...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324422/ https://www.ncbi.nlm.nih.gov/pubmed/32306129 http://dx.doi.org/10.1007/s00432-020-03217-7 |